Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:34:59 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



Q:FBIO - FORTRESS BIOTECH INC - http://fortressbiotech.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FBIO - Q0.21.74·1.880.61.75-0.05-2.8177.82717101.85  1.86  1.6711.5217  1.2416:00:32May 0215 min RT 2¢

Recent Trades - Last 10 of 710
Time ETExPriceChangeVolume
16:00:32Q1.75-0.05156
16:00:01Q1.75-0.05201
16:00:01Q1.75-0.05100
16:00:01Q1.75-0.0595
16:00:01Q1.75-0.0520
16:00:01Q1.75-0.051
16:00:01Q1.75-0.05129
16:00:01Q1.75-0.0558
16:00:01Q1.75-0.0532
16:00:01Q1.75-0.05100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-02 16:01U:FBIONews ReleaseMustang Bio Announces Closing of $4 Million Public Offering
2024-05-01 16:02U:FBIONews ReleaseJourney Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
2024-04-29 20:00U:FBIONews ReleaseMustang Bio Announces Pricing of $4 Million Public Offering
2024-04-29 08:00U:FBIONews ReleaseAvenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
2024-04-25 08:31U:FBIONews ReleaseJourney Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
2024-04-24 07:31U:FBIONews ReleaseAvenue Therapeutics Announces Reverse Stock Split
2024-03-28 16:05U:FBIONews ReleaseFortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
2024-03-28 09:01U:FBIONews ReleaseMustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
2024-03-25 08:30U:FBIONews ReleaseAvenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
2024-03-22 08:30U:FBIONews ReleaseCheckpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
2024-03-21 16:01U:FBIONews ReleaseJourney Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
2024-03-18 16:05U:FBIONews ReleaseAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
2024-03-18 08:31U:FBIONews ReleaseJourney Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
2024-03-18 08:01U:FBIONews ReleaseCheckpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
2024-03-15 08:30U:FBIONews ReleaseJourney Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
2024-03-15 08:15U:FBIONews ReleaseAvenue Therapeutics Receives Positive Listing Determination from Nasdaq
2024-03-13 08:30U:FBIONews ReleaseJourney Medical Corporation to Participate in the 36th Annual ROTH Conference
2024-03-12 08:30U:FBIONews ReleaseFortress Biotech to Participate in 36th Annual ROTH Conference
2024-03-11 08:31U:FBIONews ReleaseJourney Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
2024-03-11 08:00U:FBIONews ReleaseAvenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting